Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.37 |
| ▸ | FASN | P49327 | 3/20 | 0.37 |
| ▸ | ACP1 | P24666 | 2/20 | 0.37 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11743094 | 0.81 | FASN (0.40) | PTPN1FASNACP1CDC25BALDH1A1 | |
| SCHEMBL7428431 | 0.68 | PTPN1 (0.37) | PTPN1ACP1CDC25BALDH1A1LMNA | |
| SCHEMBL11742802 | 0.68 | PTPN1 (0.41) | PTPN1FASNACP1CDC25BALDH1A1 | |
| SCHEMBL21996373 | 0.67 | PTPN1 (0.39) | PTPN1ACP1CDC25BALDH1A1L3MBTL1 | |
| SCHEMBL10572506 | 0.66 | PTPN1 (0.40) | PTPN1ACP1CDC25BALDH1A1L3MBTL1 | |
| SCHEMBL1356857 | 0.64 | PTPN1 (0.62) | PTPN1ACP1CDC25BALDH1A1L3MBTL1 | |
| SCHEMBL9730908 | 0.64 | — | — | |
| SCHEMBL30457001 | 0.63 | ALDH1A1 (0.38) | PTPN1ACP1CDC25BALDH1A1L3MBTL1 | |
| SCHEMBL10519639 | 0.63 | PTPN1 (0.38) | PTPN1ACP1CDC25BALDH1A1L3MBTL1 | |
| SCHEMBL8306149 | 0.63 | PTPN1 (0.38) | PTPN1ACP1CDC25BALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-01-14 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010035-A1 | Novel Dual Action Receptors Antagonists (Dara) at the Ati and Eta Receptors | EDNRA, EDNRB, AGTR1 | PTPN1 2381/4885FASN 2375/4885ACP1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.